Tags

Type your tag names separated by a space and hit enter

Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel?
Curr Gastroenterol Rep. 2004 Jun; 6(3):213-9.CG

Abstract

Transient lower esophageal sphincter relaxations (TLESRs) are rapid and prolonged relaxations of the lower esophageal sphincter (LES) that are not associated with swallowing. They are the mechanism by which most gastroesophageal reflux episodes occur in normal people and in patients with esophagitis. Transient LES relaxations appear to be mediated by a vagovagal reflex initiated by gastric distention. Baclofen is a g-aminobutyric acid (GABA) derivative that inhibits the production of TLESRs by acting as a GABA(B) receptor agonist at one or more loci along the vagovagal reflex arc. Animal and human studies suggest that baclofen decreases the number of reflux events and amount of esophageal acid exposure. Baclofen or another GABA(B) receptor agonist may be clinically useful in treatment of gastroesophageal reflux disease.

Authors+Show Affiliations

Department of Internal Medicine, Cedars-Sinai Medical Center, 8635 West Third Street, Suite 770W, Los Angeles, CA 90048, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15128488

Citation

Wise, James, and Jeffrey L. Conklin. "Gastroesophageal Reflux Disease and Baclofen: Is There a Light at the End of the Tunnel?" Current Gastroenterology Reports, vol. 6, no. 3, 2004, pp. 213-9.
Wise J, Conklin JL. Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel? Curr Gastroenterol Rep. 2004;6(3):213-9.
Wise, J., & Conklin, J. L. (2004). Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel? Current Gastroenterology Reports, 6(3), 213-9.
Wise J, Conklin JL. Gastroesophageal Reflux Disease and Baclofen: Is There a Light at the End of the Tunnel. Curr Gastroenterol Rep. 2004;6(3):213-9. PubMed PMID: 15128488.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel? AU - Wise,James, AU - Conklin,Jeffrey L, PY - 2004/5/7/pubmed PY - 2004/9/24/medline PY - 2004/5/7/entrez SP - 213 EP - 9 JF - Current gastroenterology reports JO - Curr Gastroenterol Rep VL - 6 IS - 3 N2 - Transient lower esophageal sphincter relaxations (TLESRs) are rapid and prolonged relaxations of the lower esophageal sphincter (LES) that are not associated with swallowing. They are the mechanism by which most gastroesophageal reflux episodes occur in normal people and in patients with esophagitis. Transient LES relaxations appear to be mediated by a vagovagal reflex initiated by gastric distention. Baclofen is a g-aminobutyric acid (GABA) derivative that inhibits the production of TLESRs by acting as a GABA(B) receptor agonist at one or more loci along the vagovagal reflex arc. Animal and human studies suggest that baclofen decreases the number of reflux events and amount of esophageal acid exposure. Baclofen or another GABA(B) receptor agonist may be clinically useful in treatment of gastroesophageal reflux disease. SN - 1522-8037 UR - https://www.unboundmedicine.com/medline/citation/15128488/Gastroesophageal_reflux_disease_and_baclofen:_is_there_a_light_at_the_end_of_the_tunnel L2 - http://www.diseaseinfosearch.org/result/2996 DB - PRIME DP - Unbound Medicine ER -